Industry Insights AI: 12/09/24
In this week’s insights, we explore recent developments regarding the use of artificial intelligence (AI) in improving healthcare and research.
NICE releases new guidance on using AI for evidence generation
The National Institute for Health and Care Excellence (NICE) in the UK has released a new position statement on using AI to generate and report evidence for health technology assessments (#HTA). This position statement highlights the role of AI integration in systematic reviews, clinical evidence generation, real-world data (#RWD) analysis and cost-effectiveness evidence. It emphasises the potential of AI to automate processes, analyse large datasets and improve efficiency. According to NICE, AI should augment but not replace human involvement in evidence generation. Its use should be justified and aligned with ethical guidelines and regulations.
Google DeepMind introduces AlphaProteo, a new AI system for designing proteins for biological and health research
Google DeepMind has introduced AlphaProteo, an AI system capable of designing novel proteins that effectively bind to specific target molecules. This discovery may have potentially beneficial implications for drug discovery and disease research. AlphaProteo is the first AI tool to have successfully generated protein binders for various target proteins, including VEGF-A. The system has demonstrated protein binding affinities up to 300 times greater than existing methods. Despite the promising results, Google DeepMind acknowledges that AlphaProteo still shows limitations and states that it is committed to working towards improving it.
WHO releases a toolkit for the assessment of AI implementation in public health
The World Health Organization (WHO), in collaboration with the Inter-American Development Bank (IDB) and the Pan-American Health Organization (PAHO), has released an updated toolkit that aims to provide countries with guidelines on integrating AI into public health. With this toolkit, the WHO aims to help countries identify strengths and weaknesses in their capacity to implement AI ethically and successfully within their public health sectors and foster informed decision-making, strategic planning and targeted investments.
At Elion Medical Communications, we keep up-to-date with the latest in AI. Check out our other Industry Insights on LinkedIn or learn more at https://elion.nz/
